GILD - Gilead solidifies leadership in COVID-19 treatments with FDA remdesivir nod

The FDA's full approval of Gilead Sciences' (GILD) Veklury (remdesivir) on Thursday, October 22, for severely ill hospitalized COVID-19 patients was the first full nod for such a therapy and sustains the company's leadership position in antiviral treatments against SARS-CoV-2 infection. Remdesivir was also the first antiviral treatment to receive emergency use authorization ((EUA)) in the U.S., Europe, Canada, Australia and Japan to treat the respiratory infection.The company is actively working to expand the RNA polymerase inhibitor's indications. Its current U.S. EUA covers moderately ill patients and hospitalized pediatric patients under the age of 12 with certain weight restrictions.A search in ClinicalTrials.gov listed 23 ongoing or planned clinical trials on remdesivir.Four studies involve pediatric patients including a company-sponsored 52-subject Phase 2/3 study, CARAVAN, evaluating the drug in young people less than 18 years old. Primary endpoints are safety and pharmacokinetics. Secondary endpoints include efficacy measures. The estimated completion date is February

For further details see:

Gilead solidifies leadership in COVID-19 treatments with FDA remdesivir nod